Qube Research & Technologies LTD Atara Biotherapeutics, Inc. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.5 - $3.04 $52,362 - $106,120	34,908 New	34,908 $56,000
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $159,591 - $290,064	55,997 New	55,997 $183,000
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $111,012 - $232,912	-23,670 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$8.44 - $16.89 $199,774 - $399,786	23,670 New	23,670 $220,000
Q3 2021 Nov 12, 2021	SELL	$11.99 - $17.9 $235,075 - $350,947	-19,606 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $801,616 - $1.03 Million	-62,189 Reduced 76.03%	19,606 $305,000
Q1 2021 May 14, 2021	BUY	$14.0 - $20.72 $511,994 - $757,751	36,571 Added 80.87%	81,795 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $572,988 - $1.19 Million	45,224 New	45,224 $888,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.